Comparison

OrderlyMeds vs Henry Meds: transparency comparison

A like-for-like look at OrderlyMeds and Henry Meds on the facts we can state without inventing data. Because we have not independently verified pricing for at least one of these providers, this page does not rank them on price — it compares disclosed and regulatory facts only.

Pricing comparison unavailable

Comparison unavailable for pricing; transparency comparison only. We have not independently verified pricing for at least one of OrderlyMeds and Henry Meds, so we do not rank them on cost or declare a cheaper option. We do not publish estimated prices.

OrderlyMeds vs Henry Meds disclosed facts
FactorOrderlyMedsHenry Meds
Pricing verified by us?Confirm on siteConfirm on site
FDA-approved or compounded?Verify per productVerify per product
Pharmacy named publicly?Check on siteCheck on site
Regulatory statusCompounded GLP-1 is not FDA-approved; lawful 503A compounding is narrow after the resolved shortages.

To compare these two fairly, confirm each provider’s price at your maintenance dose, whether the product is compounded or FDA-approved, and which pharmacy fills it. See the pharmacy transparency comparison and total monthly cost.

What to verify

Before choosing between OrderlyMeds and Henry Meds

• Is each provider’s product compounded (not FDA-approved) or the branded drug?

• What is each total monthly cost at your maintenance dose, including fees?

• Which specific pharmacy fills each, and is it named and licensed for your state?

• Is each prescribing provider licensed where you live?

Regulatory status

Compounded GLP-1 in 2026

The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →